

Michael E Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5464310/publications.pdf>

Version: 2024-02-01

83
papers

1,968
citations

304743

22
h-index

289244

40
g-index

86
all docs

86
docs citations

86
times ranked

3169
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	3.3	213
2	Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. <i>Blood</i> , 2012, 120, 386-394.	1.4	146
3	Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. <i>Cancer</i> , 2014, 120, 548-554.	4.1	130
4	Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 1172-1181.	30.7	112
5	Career burnout among pediatric oncologists. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1168-1173.	1.5	80
6	Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 437-453.	329.8	73
7	HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. <i>Scientific Reports</i> , 2016, 6, 31154.	3.3	69
8	Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. <i>Journal of Oncology Practice</i> , 2016, 12, e388-e395.	2.5	63
9	An assessment of the current state of palliative care education in pediatric hematology/oncology fellowship training. <i>Pediatric Blood and Cancer</i> , 2009, 53, 647-651.	1.5	58
10	Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. <i>Clinical Sarcoma Research</i> , 2015, 5, 4.	2.3	55
11	Pediatric Oncologists' Views Toward the Use of Complementary and Alternative Medicine in Children With Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 177-182.	0.6	54
12	Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glebatumumab Vedotin, for the Treatment of Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 32-38.	1.5	46
13	Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. <i>Scientific Reports</i> , 2018, 8, 14294.	3.3	45
14	Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention. <i>Cancer</i> , 2020, 126, 949-957.	4.1	44
15	Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma. <i>PLoS ONE</i> , 2014, 9, e106249.	2.5	38
16	Detection of circulating tumor DNA in patients with osteosarcoma. <i>Oncotarget</i> , 2018, 9, 12695-12704.	1.8	38
17	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , 2020, 126, 3708-3718.	4.1	33
18	Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1709-1715.	2.0	32

#	ARTICLE	IF	CITATIONS
19	Disparities in Cancer Survival Among Adolescents and Young Adults: A Population-Based Study of 88â€‰%000 Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1074-1083.	6.3	32
20	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancers</i> , 2022, 14, 150.	3.7	30
21	Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). <i>Nuclear Medicine and Biology</i> , 2016, 43, 812-817.	0.6	28
22	Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. <i>Genes and Cancer</i> , 2017, 8, 484-494.	1.9	26
23	Physician perspectives on compassionate use in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27545.	1.5	23
24	Technology-Assisted Psychosocial Interventions for Childhood, Adolescent, and Young Adult Cancer Survivors: A Systematic Review and Meta-Analysis. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 6-16.	1.3	21
25	p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. <i>Scientific Reports</i> , 2019, 9, 6161.	3.3	20
26	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. <i>Cancer Medicine</i> , 2020, 9, 2146-2152.	2.8	18
27	Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. <i>Annals of Surgical Oncology</i> , 2016, 23, 990-997.	1.5	17
28	ABBV-085, Antibodyâ€“Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 535-540.	4.1	17
29	Barriers and Facilitators to Adolescent and Young Adult Cancer Trial Enrollment: NCORP Site Perspectives. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab027.	2.9	17
30	The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. <i>PLoS ONE</i> , 2017, 12, e0173322.	2.5	17
31	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1717-1725.	2.5	15
32	In vivo evaluation of the lysineâ€“specific demethylase (KDM1A/LSD1) inhibitor SPâ€“2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). <i>Pediatric Blood and Cancer</i> , 2021, 68, e29304.	1.5	14
33	Management of chemotherapyâ€“induced febrile neutropenia in pediatric oncology patients: A North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26700.	1.5	13
34	Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis: Impact of Family History. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e359-e363.	0.6	13
35	The Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network: A New Model for Addressing Site-Level Factors Impacting Clinical Trial Enrollment. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 522-527.	1.3	13
36	Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov. <i>Value in Health</i> , 2021, 24, 1820-1827.	0.3	13

#	ARTICLE	IF	CITATIONS
37	Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. <i>Cancer</i> , 2022, 128, 2455-2462.	4.1	13
38	Attitudes and Practices of Pediatric Oncologists Regarding Methadone Use in the Treatment of Cancer-related Pain. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 103-107.	0.6	12
39	Provider views on the management of Ewing sarcoma of the spine and pelvis. <i>Journal of Surgical Oncology</i> , 2018, 117, 417-424.	1.7	12
40	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. <i>Sarcoma</i> , 2020, 2020, 1-9.	1.3	12
41	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 903-913.	4.1	12
42	The feasibility of implementing a communication skills training course in pediatric hematology/oncology fellowship. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 480-490.	0.8	11
43	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1496-1504.	0.8	11
44	Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials. <i>Scientific Reports</i> , 2022, 12, 3875.	3.3	11
45	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 321-327.	2.0	10
46	Financial burden for caregivers of adolescents and young adults with cancer. <i>Psycho-Oncology</i> , 2022, 31, 1354-1364.	2.3	10
47	Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28606.	1.5	9
48	Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28970.	1.5	9
49	Patterns of National Cancer Institute-sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults. <i>Cancer Medicine</i> , 2021, 10, 7620-7628.	2.8	9
50	Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5215-5219.	5.2	9
51	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28222.	1.5	8
52	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 164-174.	1.3	8
53	Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 117-121.	1.3	8
54	Prevalence of Sleep Disturbances in Pediatric Cancer Patients and Their Diagnosis and Management. <i>Children</i> , 2021, 8, 1100.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Meal planning values impacted by the cancer experience in families with school-aged survivors—a qualitative exploration and recommendations for intervention development. <i>Supportive Care in Cancer</i> , 2020, 28, 1305-1313.	2.2	7
56	HER2-Targeted Therapy in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 55-66.	1.6	7
57	Psychosocial Distress Due to Interference of Normal Developmental Milestones in AYAs with Cancer. <i>Children</i> , 2022, 9, 309.	1.5	7
58	High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature. <i>Sarcoma</i> , 2018, 2018, 1-10.	1.3	6
59	Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute—Designated Community Oncology Research Programs. <i>JCO Oncology Practice</i> , 2020, 16, e1060-e1066.	2.9	6
60	Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 8-13.	0.8	6
61	Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. <i>Sarcoma</i> , 2021, 2021, 1-10.	1.3	6
62	Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 320-322.	1.3	6
63	CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. <i>Oncotarget</i> , 2017, 8, 87848-87859.	1.8	6
64	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1176-1184.	2.5	6
65	Exploring food preparation practices in families with and without school-aged childhood cancer survivors. <i>Public Health Nutrition</i> , 2020, 23, 410-415.	2.2	5
66	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. <i>Cancer Epidemiology</i> , 2021, 75, 102044.	1.9	5
67	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 385-386.	1.3	4
68	The case for catch-up human papillomavirus vaccination in at-risk populations: Rural communities and survivors of pediatric and young adult cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 518-519.	329.8	4
69	Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network. <i>JCO Oncology Practice</i> , 2022, 18, 224-231.	2.9	4
70	5- <i>Az</i> acitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1111-1112.	1.5	3
71	Pediatric oncologist willingness to offer germline <i>TP53</i> testing in osteosarcoma. <i>Cancer</i> , 2018, 124, 1242-1250.	4.1	3
72	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 445-452.	2.4	3

#	ARTICLE	IF	CITATIONS
73	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. <i>Oncologist</i> , 2022, 27, 135-143.	3.7	3
74	Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29390.	1.5	2
75	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 363-370.	3.7	2
76	Factors impacting adolescent and young adult cancer patients' decision to pursue genetic counseling and testing. <i>Supportive Care in Cancer</i> , 2022, 30, 5481-5489.	2.2	2
77	Provider and staff crisis well-being associated with trust in leadership and baseline burnout. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29497.	1.5	2
78	Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 453-467.	0.8	2
79	Impact of a Genetic Evaluation Initiative to Increase Access to Genetic Services for Adolescent and Young Adults at a Tertiary Cancer Hospital. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 296-302.	1.3	1
80	Minimal Reduction of PU.1 Is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 305-305.	1.4	1
81	The Children's Oncology Group (COG) Adolescent and Young Adult (AYA) Responsible Investigator (RI) Network: An initiative for advancing AYA cancer research in the National Clinical Trials Network (NCTN).. <i>Journal of Clinical Oncology</i> , 2019, 37, e18016-e18016.	1.6	1
82	Otolaryngologist and pediatric oncologist perspectives on the role of fine needle aspiration in diagnosing pediatric head and neck masses. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2019, 121, 34-40.	1.0	0
83	Pediatric oncology provider views on biopsying solid tumors in children with relapsed or refractory disease for the purpose of genomic profiling.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10566-10566.	1.6	0